Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the
efficacy, safety, and PK of chidamide in patients with R/R PTCL.
Phase:
Phase 2
Details
Lead Sponsor:
Great Novel Therapeutics Biotech & Medicals Corporation